Related Experiment Video
Updated: Aug 6, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Cutaneous T-Cell Lymphoma Treatment: Case Series of Combination Therapy With Intralesional Injections of
Michael R Lindberg1, Ashley DiLorenzo1, Jennifer A DeSimone1
1Dr. Lindberg is from the Georgetown University School of Medicine, Washington, DC. Drs. DiLorenzo and DeSimone are from the Department of Dermatology, MedStar Washington Hospital Center/Georgetown University Hospital, and the Department of Dermatology, Georgetown University. Dr. DeSimone is from the INOVA Schar Cancer Institute, Fairfax, Virginia.
Abstract:
Cutaneous T-cell lymphoma (CTCL) is a chronic form of skin cancer. Skin-directed therapies rarely achieve complete clearance of lesions, and recurrences are frequent. In this case series, 9 patients with stage IA to IVA2 CTCL received intralesional (IL) therapy with 5-fluorouracil (5-FU) and imiquimod (IMQ) cream 5% daily to recalcitrant plaques and tumors. All 9 patients attained a complete response (CR) with no recurrences reported and no severe side effects. We find that combination IL 5-FU and IMQ cream 5% daily is a well-tolerated, effective, and durable skin-directed therapy for recalcitrant plaques and tumors in CTCL.
Related Concept Videos
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

